231 related articles for article (PubMed ID: 35220997)
1. Farnesoid X Receptor as a Promising Therapeutic Target for Nonalcoholic Fatty Liver Disease (NAFLD) and the Current Development of Its Agonists.
Shen T; Shi A; Wei Y; Luo X; Xi L
Discov Med; 2021; 32(167):113-121. PubMed ID: 35220997
[TBL] [Abstract][Full Text] [Related]
2. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease.
Wang J; Yang N; Xu Y
Am J Chin Med; 2024; 52(2):291-314. PubMed ID: 38480498
[TBL] [Abstract][Full Text] [Related]
3. A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development.
Tang Y; Fan Y; Wang Y; Wang D; Huang Q; Chen T; Cao X; Wen C; Shen X; Li J; You Y
Biomed Pharmacother; 2024 Jun; 175():116658. PubMed ID: 38701562
[TBL] [Abstract][Full Text] [Related]
4. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR).
Zhou S; You H; Qiu S; Yu D; Bai Y; He J; Cao H; Che Q; Guo J; Su Z
Biomed Pharmacother; 2022 Oct; 154():113577. PubMed ID: 35988420
[TBL] [Abstract][Full Text] [Related]
5. Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4.
Deng W; Fan W; Tang T; Wan H; Zhao S; Tan Y; Oware KA; Tan J; Li J; Qu S
Oxid Med Cell Longev; 2022; 2022():3589525. PubMed ID: 35251469
[TBL] [Abstract][Full Text] [Related]
6. Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor.
Zheng Z; Zhao Z; Li S; Lu X; Jiang M; Lin J; An Y; Xie Y; Xu M; Shen W; Guo GL; Huang Y; Li S; Zhang X; Xie W
Mol Pharmacol; 2017 Oct; 92(4):425-436. PubMed ID: 28739572
[TBL] [Abstract][Full Text] [Related]
7. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
8. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
Xi Y; Li H
Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
[TBL] [Abstract][Full Text] [Related]
9. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
Radun R; Trauner M
Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
[TBL] [Abstract][Full Text] [Related]
10. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.
Carr RM; Reid AE
Curr Atheroscler Rep; 2015 Apr; 17(4):500. PubMed ID: 25690590
[TBL] [Abstract][Full Text] [Related]
11. Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease.
Qin T; Gao X; Lei L; Feng J; Zhang W; Hu Y; Shen Z; Liu Z; Huan Y; Wu S; Xia J; Zhang L
Eur J Med Chem; 2023 Apr; 252():115307. PubMed ID: 37003047
[TBL] [Abstract][Full Text] [Related]
12. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
13. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease.
Kim SG; Kim BK; Kim K; Fang S
Endocrinol Metab (Seoul); 2016 Dec; 31(4):500-504. PubMed ID: 28029021
[TBL] [Abstract][Full Text] [Related]
14. Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease.
Jin L; Wang R; Zhu Y; Zheng W; Han Y; Guo F; Ye FB; Li Y
Sci Rep; 2015 Dec; 5():17288. PubMed ID: 26620317
[TBL] [Abstract][Full Text] [Related]
15. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
[TBL] [Abstract][Full Text] [Related]
16. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
Xu JY; Li ZP; Zhang L; Ji G
World J Gastroenterol; 2014 Oct; 20(37):13493-500. PubMed ID: 25309079
[TBL] [Abstract][Full Text] [Related]
17. [Advances in traditional Chinese medicine treatment of non-alcoholic fatty liver disease via farnesoid X receptor].
Zhao HH; Cui J; Zhang JJ; Chen JX; Shi AH; Zhu XS
Zhongguo Zhong Yao Za Zhi; 2023 Dec; 48(24):6582-6591. PubMed ID: 38212018
[TBL] [Abstract][Full Text] [Related]
18. Role of FXR in the development of NAFLD and intervention strategies of small molecules.
Long J; Xu Y; Zhang X; Wu B; Wang C
Arch Biochem Biophys; 2024 Jul; 757():110024. PubMed ID: 38703803
[TBL] [Abstract][Full Text] [Related]
19. FXR-mediated inhibition of autophagy contributes to FA-induced TG accumulation and accordingly reduces FA-induced lipotoxicity.
Wu K; Zhao T; Hogstrand C; Xu YC; Ling SC; Chen GH; Luo Z
Cell Commun Signal; 2020 Mar; 18(1):47. PubMed ID: 32192487
[TBL] [Abstract][Full Text] [Related]
20. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
